Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Last trade$0.2694
Day change-$0.0149 (-5.24%)
Day range$0.267 – $0.287
Volume1,731,126
Market cap$54M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$53.28M
Price / earnings
—
Price / book
7.71×
Price / sales
0.35×
EV / sales
1.16×
EV / EBITDA
-20.07×
Profitability
Earnings per share
-$0.18
Return on assets
-13.5%
Return on equity
-492.89%
Dividend yield
0%
Liquidity and leverage
Debt / equity
20.65×
Current ratio
2.49×
Quick ratio
1.51×
Cash ratio
0.22×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HRTX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$37.67M
$34.71M
$40.59M
$38.21M
$37.2M
$38.9M
$40.78M
$32.81M
Cost of revenue
$11.57M
$10.64M
$11.12M
$11.91M
$9.86M
$8.46M
$10.23M
$9.46M
Gross profit
$26.09M
$24.07M
$29.47M
$26.3M
$27.34M
$30.45M
$30.55M
$23.35M
Selling, general and administrative
$25.44M
$26.45M
$25.69M
$26.92M
$26.05M
$25.01M
$23.2M
$23.35M
Research and development
$2.7M
$2.39M
$3.75M
$3.47M
$2.93M
$2.28M
$3.18M
$4.47M
Total operating expenses
$28.14M
$28.84M
$29.43M
$30.39M
$28.98M
$27.29M
$26.38M
$27.81M
Operating income
-$2.04M
-$4.77M
$38K
-$4.09M
-$1.64M
$3.15M
$4.17M
-$4.46M
Interest expense
$0
$0
-$9.61M
$0
$0
$0
-$6.03M
$0
Income before taxes
-$5.49M
-$8.11M
-$2.95M
-$17.5M
-$2.38M
$2.64M
$3.66M
-$4.85M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.49M
-$8.11M
-$2.95M
-$17.5M
-$2.38M
$2.64M
$3.66M
-$4.85M
Net income attributable to common shareholders
-$5.49M
-$8.11M
-$2.95M
-$17.5M
-$2.38M
$2.64M
$3.66M
-$4.85M
EBITDA
-$1.59M
-$4.24M
$575K
-$3.48M
-$1.03M
$3.71M
$4.75M
-$3.88M
Basic earnings per share
-$0.03
-$0.04
-$0.02
-$0.10
-$0.02
$0.02
$0.02
-$0.03
Diluted earnings per share
-$0.03
-$0.04
-$0.02
-$0.10
-$0.02
$0.01
$0.02
-$0.03
Recent news
Company coverage with links to the original publishers.
Xencor (XNCR) reported quarterly earnings of $0.5 per share, significantly beating the consensus estimate of a loss of $0.35 per share, with revenues of $116.52 million surpassing estimates by 76.89%. Despite the strong earnings surprise of +242.86%, the stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The company has outperformed the S&P 500 by 100.1% year-to-date, but analysts expect underperformance in the near term.
Heron Therapeutics, Inc. announced it will host a conference call on November 9, 2026, to report third quarter financial results and discuss business highlights. The company reported Q2 2026 net revenue of $37.7 million, up 9% from Q1 2026, with ZYNRELEF net revenue growing 35% and APONVIE net revenue growing 74% year-over-year.
Heron Therapeutics announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of investment management and corporate finance experience, most recently serving as a Managing Director at Starboard Value LP.
Heron Therapeutics, a commercial-stage biotechnology company, will host a conference call on November 12, 2024, to report its third quarter 2024 financial results and discuss recent business highlights.
The global chemotherapy-induced nausea and vomiting treatment market is expected to grow at a CAGR of 6.4% and reach a valuation of US$ 12,688.0 million by 2034, driven by the increasing incidence of cancer and the need for effective management of CINV.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.